|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
Pacira Wins FDA Approval of Pain Drug, Cushioning Pain of 3Q Loss
|
Arlene Weintraub |
10/31/11 |
New York
|
|
AdverseEvents.com Seeks to Keep Track of Drug Side Effects the Way the FDA Never Could
|
Luke Timmerman |
09/27/11 |
San Francisco
|
|
Nevro Raises $58M for Anti-Pain Device
|
Wade Roush |
07/20/11 |
San Francisco
|
|
Pfizer buys Icagen
|
Arlene Weintraub |
07/20/11 |
New York
|
|
Institutes Of Medicine Pain Report May Aid Medical Device Makers
|
Thomas Lee |
07/14/11 |
Boston
|
|
Durect Plunges on FDA Ruling
|
Arlene Weintraub |
06/24/11 |
San Francisco
|
|
BioNanomatrix Moves HQ, Awarepoint CEO Talks Strategy, Ambit Raises $30 Million, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/16/11 |
San Diego
|
|
AcelRx Prices IPO
|
Wade Roush |
01/21/11 |
San Francisco
|
|
Omeros Nabs $25M from Paul Allen, State Life Sciences Fund to Pursue Elusive Drug Targets
|
Luke Timmerman |
10/25/10 |
Seattle
|
|
Zogenix Files for IPO, Orexigen Licenses Obesity Drug to Takeda, ImThera Raises Capital For Sleep Apnea, & More San Diego Life Science News
|
Bruce V. Bigelow |
09/09/10 |
San Diego
|
|
San Diego’s Zogenix Files for $90M IPO to Expand Development of Needle-Free Injector and Pain Drugs
|
Bruce V. Bigelow |
09/07/10 |
San Diego
|
|
San Diego’s Zogenix Moving Fast to Commercialize Drug-and-Device Combo
|
Bruce V. Bigelow |
08/17/10 |
San Diego
|
|
Ascent Changes to Anchor
|
Erin Kutz |
03/30/10 |
Boston
|
|
Cadence Pharmaceuticals’ Pain Reliever Handed Second Regulatory Setback
|
Denise Gellene |
02/11/10 |
San Diego
|
|
Javelin Pharma Agrees to Merger with Myriad Pharma
|
Ryan McBride |
12/21/09 |
Boston
|
|
Hydra, Cubist Seek New Pain Drugs
|
Luke Timmerman |
10/19/09 |
Boston
|
|
Cadence, Aiming to Reduce Narcotics Use in Hospitals, Gears Up to Market IV Pain Reliever
|
Luke Timmerman |
07/07/09 |
San Diego
|
|
Cadence Applies for FDA Approval
|
Luke Timmerman |
05/14/09 |
San Diego
|
|
Alkermes, Swinging For the Fence, Touts New Anti-Addiction Drug
|
Luke Timmerman |
04/07/09 |
Boston
|
|
And Then There Were 3 at TorreyPines Therapeutics
|
Juha-Pekka Tikka |
04/01/09 |
San Diego
|
|
Pfizer’s VC Leader, Barbara Dalton, on Corporate Venture and Northwest Deal Hunting
|
Luke Timmerman |
03/17/09 |
Seattle
|
|
Cadence Drug Fails to Prevent Hospital Infections; Company Scraps Program
|
Luke Timmerman |
03/12/09 |
San Diego
|
|
Biogen Idec Aims to Regenerate Damaged Nerves, Crack Multi-Billion Dollar Market
|
Luke Timmerman |
03/11/09 |
Boston
|
|
Cadence Raises $86.6M in Private Stock Offering
|
Luke Timmerman |
02/17/09 |
San Diego
|
|
Stopping Migraines Before They Hurt: NeurAxon Pursues New Pain Drug
|
Luke Timmerman |
02/02/09 |
Boston
|
|
Cadence Turns Attention to Marketplace, as IV Pain Reliever Reaches Goals in Clinical Trials
|
Luke Timmerman |
12/18/08 |
San Diego
|
|
Cadence Shares Boom as IV Pain Reliever Reaches Goal in Study
|
Luke Timmerman |
12/17/08 |
San Diego
|
|
Seattle’s Pharma Godfather, Ben Shapiro, Sees Potential Here To Transform Medicine Despite Setbacks
|
Luke Timmerman |
11/17/08 |
Seattle
|
|
Impel NeuroPharma Develops Novel Delivery System to Get Drugs Into the Brain
|
Luke Timmerman |
08/29/08 |
Seattle
|
|
No Headache for NeurAxon: Company Closes $32 Million Financing Round
|
Robert Buderi |
08/20/07 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.